Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...

The company's fresh look at psychedelic drugs is attracting lots of attention. Can the highly refined version of magic mushrooms that Compass Pathways is developing for depression give your portfolio ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...